Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03634969 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03634969: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03634969 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03634969, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.
Interventions
- DRUG BMS-986224
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2019-04-30 |
| Phase | Phase 1 |
What the finished NCT03634969 record still lists
NCT03634969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 1 intervention - of which BMS-986224 is the first listed.
NCT03634969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03634969 about?
NCT03634969 is a clinical study titled "An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants". The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.
What is the current status of trial NCT03634969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-08-14. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03634969?
The interventions under investigation include: BMS-986224 (DRUG).
Who is sponsoring clinical trial NCT03634969?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03634969's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI